Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 10, Issue 4, 2009, Pages 185-189

  Doulton, Timothy Wr ^a   MacGregor, Graham A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aliskiren; Combinations; Hypertension; Proteinuria; Renin inhibitor

Indexed keywords

ALISKIREN; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; POTASSIUM; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEART INFARCTION; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 73349091588     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320309342733     Document Type: Article

References (48)

1. Williams B., Poulter NR, Brown MJ et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004 ; 18: 139-185. (Pubitemid 38425770)
2. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 ; 349: 1893-1906.
3. Dickstein K., Kjekshus J. for the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 ; 360: 752-760.
4. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998 ; 97: 2202-2212.
5. Lee VC, Rhew DC, Dylan M., Badamgarav E., Braunstein GD, Weingarten SR Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004 ; 141: 693-704.
6. Flather MD, Yusuf S., Køber L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000 ; 355: 1575-1581.
7. Yusuf S. for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 ; 324: 145-153. (Pubitemid 30051645)
8. Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 ; 345: 861-869. (Pubitemid 34940825)
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993 ; 329: 1456-1462.
10. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy in type 2 diabetes. N Engl J Med 2001 ; 345: 851-860.
11. Jafar TH, Schmid CH, Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease: a meta-analysis of patient level data. Ann Intern Med 2001 ; 135: 73-87.
12. Giatras I., Lau J., Levey AS for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 2001 ; 127: 337-345.
13. van den Meiracker AH, Man in ĝ€?t Veld AJ, Admiraal PJ et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992 ; 10: 803-812.
14. Mooser V., Nussberger J., Juillerat L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990 ; 15: 276-282.
15. Urata H., Kinoshita A., Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990 ; 265: 22348-22357.
16. Okunishi H., Miyazaki M., Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984 ; 2: 277-284.
17. Hollenberg NK, Fisher ND, Price DA Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998 ; 32: 387-392.
18. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993 ; 11: 1155-1159.
19. Petrie MC, Padmanabhan N., McDonald JE, Hillier C., Connell JM, McMurray JJ Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001 ; 37: 1056-1061.
20. Gainer JV, Morrow JD, Loveland A., King DJ, Brown NJ Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998 ; 339: 1285-1292.
21. Doulton TWR, He FJ, MacGregor GA Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005 ; 45: 880-886.
22. Forclaz A., Maillard M., Nussberger J., Brunner HR, Burnier M. Angiotensin II receptor blockade. Is there truly a benefit of adding an ACE inhibitor? Hypertension 2003 ; 41: 31-36.
23. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003 ; 361: 117-124. (Pubitemid 36092015)
24. Morgan T., Anderson A., Bertram D., MacInnis RJ Effect of candesartan alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 2004 ; 5: 64-71.
25. McMurray JJ, Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting- enzyme inhibitors: the CHARM-Added trial. Lancet 2003 ; 362: 767-771.
26. Cohn JN, Tognoni G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 ; 345: 1667-1675.
27. Azizi M., Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004 ; 109: 2492-2499.
28. Mogensen CE, Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000 ; 321: 1440-1444.
29. Yusuf S., Teo KK, Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 ; 358: 1547-1559.
30. Wood JM, Maibaum J., Rahuel J. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003 ; 308: 698-705.
31. Rahuel J., Rasetti V., Maibaum J. et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000 ; 7: 493-504.
32. Azizi M., Webb R., Nussberger J., Hollenberg NK Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2005 ; 24: 243-256.
33. Nussberger J., Wuerzner G., Jensen C., Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002 ; 39 (1). E1-8.
34. Stanton A., Jensen C., Nussberger J., Oĝ€™Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003 ; 42: 1137-1143.
35. Gradman AH, Schmieder RE, Lins RL, Nussberger J., Chiang Y., Bedigian MP Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 ; 111: 1012-1018.
36. Villamil A., Chrysant SG, Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 ; 25: 217-226.
37. Oĝ€™Brien E., Barton J., Nussberger J. et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007 ; 49: 276-284.
38. Drummond W., Munger MA, Rafique Essop M., Maboudian M., Khan M., Keefe DL Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007 ; 9: 742-750.
39. Oh BH, Mitchell J., Herron JR, Chung J., Khan M., Keefe DL Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007 ; 49: 1157-1163.
40. Azizi M., Ménard J., Bissery A., Guyene TT, Bura-Riviä?re A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007 ; 2: 947-955.
41. Azizi M., Ménard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004 ; 15: 3126-3133.
42. Uresin Y., Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007 ; 8: 190-198.
43. Pool JL, Schmieder RE, Azizi M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007 ; 20 (1). 11-20.
44. Oparil S., Yarows SA, Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007 ; 370: 221-229.
45. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996;9(633-643):75S-81S. 46
46. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46:569-76.
47. Kelly DJ, Zhang Y., Moe G., Naik G., Gilbert RE Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007 ; 50: 2398-2404.
48. Parving HH, Persson F., Lewis JB, Lewis EJ, Hollenberg NK Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 ; 358: 2433-2446.